S&P 500
(0.12%) 5 303.27 points

Dow Jones
(0.34%) 40 004 points

Nasdaq
(-0.07%) 16 686 points

Oil
(0.05%) $80.10

Gas
(1.71%) $2.67

Gold
(0.96%) $2 440.70

Silver
(3.87%) $32.47

Platinum
(0.98%) $1 100.70

USD/EUR
(-0.08%) $0.919

USD/NOK
(-0.12%) $10.66

USD/GBP
(-0.01%) $0.787

USD/RUB
(0.06%) $91.02

Realtime updates for Formycon AG [FYB.DE]

Exchange: XETRA Sector: Biotechnology Industry: Biotechnology

Last Updated17 May 2024 @ 11:36

25% discount on Stockinvest.us - Use code: Podcast

0.00% € 44.30

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 11:36):

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials...

Stats
Today's Volume	16 595.00
Average Volume	8 966.00
Market Cap	782.20M
EPS	€0 ( 2024-05-08 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	9.39
ATR14	€0.191 (0.43%)

Volume Correlation

Long: -0.04 (neutral)

Short: -0.79 (moderate negative)

Signal:(56.226) Neutral

Formycon AG Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Formycon AG Correlation - Currency/Commodity

0.03
( neutral )

0.07
( neutral )

-0.06
( neutral )

0.06
( neutral )

-0.43
( neutral )

-0.01
( neutral )

Formycon AG Financials

Annual	2023
Revenue:	€77.70M
Gross Profit:	€23.31M (30.00 %)
EPS:	€4.76

FY	2023
Revenue:	€77.70M
Gross Profit:	€23.31M (30.00 %)
EPS:	€4.76

FY	2022
Revenue:	€42.50M
Gross Profit:	€12.07M (28.41 %)
EPS:	€2.62

FY	2021
Revenue:	€36.97M
Gross Profit:	€1.01M (2.72 %)
EPS:	€-1.225

Financial Reports:

No articles found.

Formycon AG Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Formycon AG

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.